Login to Your Account



Genmab Stopping Phase II, III Trials Of HuMax-CD4 In RA

By Karen Young


Thursday, September 26, 2002
Genmab A/S said Wednesday it is winding down its anti-CD4 development program for rheumatoid arthritis after initial Phase II trial results showed no significant difference in American College of Rheumatology scores for patients who received placebo vs. those treated with HuMax-CD4. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription